Is Medicamen Organ. overvalued or undervalued?

As of 19 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.80, an EV to EBITDA of 8.02, and a Price to Book Value of 1.04. These ratios suggest that the stock is trading at a significant discount compared to its earnings and assets.
In comparison to its peers, Medicamen Organ. stands out with a much lower PE ratio than Sun Pharma. Industries at 37.07 and Divi's Lab at 68.85, both of which are classified as expensive. Additionally, while Cipla and Dr. Reddy's Labs are also attractive, their PE ratios of 22.64 and 18.06, respectively, are still considerably higher than that of Medicamen. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -49.17% compared to the Sensex's 10.18%, reinforcing the notion that Medicamen Organ. is undervalued in the current market environment.